Titre du document / Document title

Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis

Auteur(s) / Author(s)

Lanzoprazole Group, ETATS-UNIS
CASTELL D. O. ; RICHTER J. E. ; ROBINSON M. ; SONTAG S. J. ; HABER M. M. ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

The Graduate Hospital, Philadelphia, Pennsylvania, ETATS-UNIS
Cleveland Clinic Foundation, Cleveland, Ohio, ETATS-UNIS
University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, ETATS-UNIS
Veterans Administration Medical Center, Hines, Illinois, ETATS-UNIS
Medical College of Pennsylvania and Hahnemann University, Philadelphia, Pennsylvania, ETATS-UNIS

Résumé / Abstract

Objectives : This study was designed to compare lansoprazole 30 mg, lansoprazole 15 mg, omeprazole 20 mg, and placebo in the treatment of erosive reflux esophagitis. Methods : In a double-blind, multicenter study, 1284 patients with endoscopically diagnosed erosive reflux esophagitis were randomized to received lansoprazole 30 mg (n = 422), lansoprazole 15 mg (n = 218), omeprazole 20 mg (n = 431), or placebo (n = 213) once daily for 8 wk. At 2, 4, 6, and 8 wk, healing was evaluated endoscopically. Patients kept daily diaries of symptoms. Results : Healing rates at 2, 4, 6, and 8 wk were 65.3%, 83.3%, 89.4%, and 90.0%, respectively, for lansoprazole 30 mg ; 56.3%, 74.6%, 80.3%, and 78.8% for lansoprazole 15 mg ; 60.9%, 82.0%, 89.7%, and 90.7% for omeprazole 20 mg ; and 23.9%, 32.8%, 36.6%, and 40.0% for placebo (all active treatments higher than placebo, p < 0.001). Healing rates with lansoprazole 30 mg were significantly higher than with lansoprazole 15 mg at all time points (p < 0.05). Healing rates with omeprazole 20 mg were significantly higher than with lansoprazole 15 mg at 4, 6, and 8 wk and were similar to those with lansoprazole 30 mg. Based on patient diaries, lansoprazole 30 mg produced better symptomatic relief than lansoprazole 15 mg or omeprazole 20 mg, primarily early in the treatment course. Conclusions : Both lansoprazole 30 mg and omeprazole 20 mg were more effective than lansoprazole 15 mg in esophageal mucosal healing. Compared with omeprazole 20 mg, lansoprazole 30 mg was as safe, was similarly effective with respect to esophageal healing, and provided superior symptomatic relief, primarily early in treatment. Lansoprazole 30 mg provided greater symptomatic relief than lansoprazole 15 mg.

Revue / Journal Title

The American journal of gastroenterology   ISSN 0002-9270 

Source / Source

Congrès
Annual Scientific Meeting American College of Gastroenterology N^o61, Seattle, Washington , ETATS-UNIS (21/10/1996)
1996, vol. 91, n^o 9, pp. 1881-2047 (26 ref.), pp. 1749-1757

Langue / Language

Anglais

Editeur / Publisher

Blackwell Publishing, Oxford, ROYAUME-UNI  (1954) (Revue)

Mots-clés anglais / English Keywords

Gastroesophageal reflux ; Erosion ; Mucosa ; Biological effect ; Chemotherapy ; Antisecretory agent ; Safety ; Effective dose ; Treatment efficiency ; Human ; Digestive diseases ; Esophageal disease ;

Mots-clés français / French Keywords

Reflux gastrooesophagien ; Erosion ; Muqueuse ; Effet biologique ; Chimiothérapie ; Antisécrétoire ; Lansoprazole ; Sécurité ; Dose efficace ; Efficacité traitement ; Homme ; Appareil digestif pathologie ; Oesophage pathologie ;

Mots-clés espagnols / Spanish Keywords

Reflujo gastroesofágico ; Erosión ; Mucosa ; Efecto biológico ; Quimioterapia ; Antisecretorio ; Seguridad ; Dosis eficaz ; Eficacia tratamiento ; Hombre ; Aparato digestivo patología ; Esófago patología ;

Localisation / Location

INIST-CNRS, Cote INIST : 11062, 35400006425194.0130